Compound 11
2-chloro-N-(3-((1-(1-(pentan-2-yl)piperidin-4-yl)-3-(3-(trifluoromethyl)phenyl)ureido)methyl)benzyl)acetamide
From: Blocking an N-terminal acetylation–dependent protein interaction inhibits an E3 ligase
Synthetic procedure: See article for the definitive version of this procedure and for full experimental details.
Average Purity (ELSD/UV): 99%. 1H NMR (500 MHz, Chloroform-d) δ 7.71 (s, 1H), 7.39 – 7.26 (m, 4H), 7.26 – 7.17 (m, 4H), 6.96 (bs, 1H), 4.57 (s, 2H), 4.57 – 4.49 (m, 1H), 4.44 (d, J = 5.9 Hz, 2H), 4.06 (s, 2H), 3.20 – 3.05 (m, 2H), 2.93 (bs, 1H), 2.79 – 2.56 (m, 2H), 2.35 – 2.10 (m, 2H), 1.84 (d, J = 13.3 Hz, 2H), 1.75 (bs, 1H), 1.53 – 1.22 (m, 3H), 1.18 (d, J = 6.5 Hz, 3H), 0.93 (t, J = 6.9 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 166.3, 155.5, 139.6, 138.7, 138.3, 131.0 (q, J = 32.0 Hz), 129.6, 129.2, 127.2, 125.7, 125.4, 124.0 (q, J = 272.6 Hz), 123.1, 119.6 (q, J = 4.0 Hz), 116.7 (q, J = 4.0 Hz), 60.8, 51.6, 49.0, 47.2, 46.0, 43.5, 42.7, 33.9, 28.2, 19.8, 13.9, 13.8. LRMS (APCI+) m/z calcd for C28H37ClF3N4O2 [M+H]+ 553.3, found 553.4.
- PubChemID:
-
336287078
- MDL Molfile:
- ChemDraw:
